• 1
    Cox A, Skipper J, Chen Y, Henderson R, Darrow T, Shabanowitz J, Engelhard V, Hunt D, Slingluff C Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Ovid Science 1994; 264: 7169.
  • 2
    Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369: 6771.
  • 3
    Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 14537.
  • 4
    Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 48995.
  • 5
    Jaeger E, Gnjatic S, Nagata Y, Stockert E, Jaeger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffmann E, Arand M, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97: 12198203.
  • 6
    Reynolds SR, Zeleniuch-Jaquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003; 9: 65762.
  • 7
    Jaeger E, Maeurer MJ, Hoehn H, Karbach J, Jaeger D, Zidianakis Z, Bakshandeh-Bath A, Orth J, Neukirch C, Necker A, Reichert TE, Knuth A. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000; 86: 53847.
  • 8
    Visseren MJ, van Elsas A, van der Voort EI, Ressing ME, Kast WM, Schrier PI, Melief CJ. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995; 154: 39918.
  • 9
    Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, Bordignon C, Sensi M, Parmiani G, Traversari C. Translation of a retained intron in tyrosinase-related protein (TRP) 2ámRNA generates a new cytotoxic t lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 1998; 188: 1005.
  • 10
    Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 19148.
  • 11
    Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appelle E, Engelhard VH. Characterization of peptides bound to the class I MHC molecules HLA-A2.1 by mass spectrometry. Science 1992; 255: 12613.
  • 12
    Henderson RA, Cox AL, Sakaguchi K, Appella E, Shabanowitz J, Hunt DF, Engelhard VH. Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. Proc Natl Acad Sci USA 1993; 90: 102759.
  • 13
    Charlton RK, Zmijewski CM. Soluble HL-A7 antigen: localization in the beta-lipoprotein fraction of human serum. Science 1970; 170: 6367.
  • 14
    van Rood JJ, van Leeuwen A, van Santen MC. Anti HL-A2 inhibitor in normal human serum. Nature 1970; 226: 3667.
  • 15
    Barnea E, Beer I, Patoka R, Ziv T, Kessler O, Tzehoval E, Zavazava N, Admon A. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol 2002; 32: 21322.
  • 16
    Stuber G, Leder GH, Storkus MT, Lotze MT, Modrow S, Szekely L, Wolf H, Klein E, Karre K, Klein G. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol 1994; 24: 7658.
  • 17
    Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 313542.
  • 18
    Rammensee H-G, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993; 11: 21344.
  • 19
    Rammensee H-G, Bachmann J, Emmerich N, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 2139.
  • 20
    Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2298.
  • 21
    Kautiainen TL, Jones PA. DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J Biol Chem 1986; 261: 15948.
  • 22
    el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, Baylin SB. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci USA 1991; 88: 34704.
  • 23
    Moretta A, Moretta L. HLA class I specific inhibitory receptors. Curr Opin Immunol 1997; 9: 694701.
  • 24
    Rammensee H-G, Bevan MJ. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 1984; 308: 7414.
  • 25
    Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003; 33: 615.
  • 26
    Goffin J, Eisenhauer E. DNA methyltransferase inhibitors—state of the art. Ann Oncol 2002; 13: 1699716.